Paying users zone. Data is covered by 
.
Get 1 month access to Gilead Sciences Inc. for $17.99, or
get full access to entire website for at least 3 months from $49.99.
We accept:
Gilead Sciences Inc. (GILD)
Enterprise Value to FCFF (EV/FCFF)
Difficulty: Intermediate
Free Cash Flow to The Firm (FCFF)
Gilead Sciences Inc., FCFF calculation
USD $ in millions
Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).
| Item | Description | The company |
|---|---|---|
| FCFF | Free cash flow to the firm is the cash flow available to the Gilead Sciences Inc.’s suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made. | Gilead Sciences Inc.’s FCFF declined from 2016 to 2017 and from 2017 to 2018. |
Interest Paid, Net of Tax
Gilead Sciences Inc., interest paid, net of tax calculation
USD $ in millions
Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).
2 2018 Calculation
Interest paid, net of amounts capitalized, tax = Interest paid, net of amounts capitalized × EITR
= × =
Enterprise Value to FCFF Ratio, Current
Gilead Sciences Inc., current EV/FCFF calculation, comparison to benchmarks
| Selected Financial Data (USD $ in millions) | |
| Enterprise value (EV) | |
| Free cash flow to the firm (FCFF) | |
| Ratio | |
| EV/FCFF | |
| Benchmarks | |
| EV/FCFF, Competitors1 | |
| Abbott Laboratories | |
| AbbVie Inc. | |
| Allergan PLC | |
| Amgen Inc. | |
| Biogen Inc. | |
| Bristol-Myers Squibb Co. | |
| Celgene Corp. | |
| Eli Lilly & Co. | |
| Johnson & Johnson | |
| Merck & Co. Inc. | |
| Pfizer Inc. | |
| Regeneron Pharmaceuticals Inc. | |
| EV/FCFF, Sector | |
| Pharmaceuticals & Biotechnology | |
| EV/FCFF, Industry | |
| Health Care | |
Based on: 10-K (filing date: 2019-02-26).
1 Click competitor name to see calculations.
If company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.
Enterprise Value to FCFF Ratio, Historical
Gilead Sciences Inc., historical EV/FCFF calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| Enterprise value (EV)1 | |
|
|
|
|
|
| Free cash flow to the firm (FCFF)2 | |
|
|
|
|
|
| Ratio | ||||||
| EV/FCFF3 | |
|
|
|
|
|
| Benchmarks | ||||||
| EV/FCFF, Competitors4 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| EV/FCFF, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| EV/FCFF, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).
3 2018 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =
4 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| EV/FCFF | Enterprise value to free cash flow to the firm is whole company valuation indicator. | Gilead Sciences Inc.’s EV/FCFF ratio increased from 2016 to 2017 and from 2017 to 2018. |